anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Acute kidney injury (AKI) is a major complication following cardiac surgery with a high incidence in those with existing kidney dysfunction. Platelet distribution width (PDW) reflects variability in platelet size and serves as an indicator of platelet activation. Recent investigations linked PDW changes to kidney pathology, suggesting its utility in identifying individuals at risk for AKI, thus necessitating exploration of its predictive value.
METHODS: Patients with preoperative renal dysfunction [15 ≤ estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2] who underwent cardiac surgery from January 2018 to December 2021 were retrospectively enrolled. PDW values were measured preoperatively and again upon admission to the ICU immediately after cardiac surgery, with the change in PDW (dPDW) defined as the difference between these two measurements. The primary outcome was postoperative AKI, defined base on the Kidney Disease: Improving Global Outcomes (KDIGO) definition and staging criteria. Multivariate regression models were performed to identify the association between dPDW and AKI and its potential trend. Restricted cubic spline analysis assessed non-linear associations between dPDW and AKI. The Youden index identified an optimal dPDW cut-off for AKI prediction. Subgroup analysis was performed to elucidate the consistency of these associations across the various subgroups.
RESULTS: AKI occurred in 53.10% (513/966) of patients, accompanied by significant PDW increases in cases of AKI (P < 0.001). After adjusting confounders, dPDW was identified as a significant risk factor for AKI [odds ratio (OR) = 1.09, 95% confidence interval (CI): (1.02 ~ 1.16), P = 0.012]. Patients in the highest dPDW quartile (Q4) had a 195% higher AKI risk compared to those in the lowest quartile (Q1) (OR = 2.95, 95% CI:1.78 ∼ 4.90, P < 0.001). Trend analysis indicates that the risk of AKI increased with higher dPDW quartiles (P for trend < 0.001). Youden index showed that dRDW = 1.1 was identified as the optimal diagnostic cut-off value for AKI. Subgroup analyses and interaction tests showed a robust association between dPDW and AKI in all subgroups (P for interaction > 0.05).
CONCLUSIONS: This study underscored perioperative PDW changes as a significant predictor of postoperative AKI in patients with renal insufficiency, highlighting its potential in refining risk stratification and management strategies.
CLINICAL TRIAL NUMBER: Not applicable for this observational retrospective study.
The present invention relates to α-salidroside, and a preparation method therefor and an application thereof. The present invention provides novel salidroside, i.e., α-salidroside. Compared with known β-salidroside, in terms of scavenging DPPH free radicals and hydroxyl free radicals, α-salidroside has activity better than that of β-salidroside, and can be added to cosmetics or anti-fatigue healthcare products as a new functional ingredient. In the preparation method for α-salidroside of the present invention, by using cheap starch, etc. as a glycosyl donor and tyrosol as a substrate, under the action of a glycosyltransferase, α-salidroside is synthesized. The glycosyltransferase has strict specificity and chiral catalytic capability, and can specifically generate α-salidroside.
The burden to participants will be minimized to enhance retention. Patients in the usual care arm receive the current "gold standard" of treatment. The patients in the intervention arm are assigned to a PN, who helps to reduce the barriers to care that could negatively impact the patients' receipt of LDTCI. The telephone-administered survey is administered to all study participants at baseline and at 3-, 6-, and 12-months post-enrollment. It takes approximately 30-40 minutes to administer. The telephone mode of survey administration was chosen to reduce the number of visits that would be required by each patient. Interviews are scheduled at the convenience of the study participants. To further reduce burden to the study participants, the interviewers offer breaks during the interview process. Patients in both arms undergo standard therapy visits. Patients in the navigation arm receive standard therapy visits plus the navigation intervention. Outside of the standard therapy visits, no additional clinic visits are required of the study participants.

Once informed consent has been obtained and the informed consent document is received, the SSC/PN will communicate to the MUSC HCC study staff the participant's contact information and that the participant is ready for baseline survey administration. All the study surveys will be administered by trained MUSC HCC study staff via telephone. A survey answer guide will be provided to the participant either in-person or via mail prior to administration of the baseline survey.
WON is first identified using EUS and punctured using a 19 gauge needle. 10 ml of fluid is aspirated and sent for gram stain and culture with sensitivities. Using a catheter-based stent delivery system with a 15mm AXIOS stent mounted onto it is inserted into the echoendoscope, and introduced into the WON cavity so that the stent lies within both the WON and enteric lumen. The stent is then deployed so that one flange of the stent is located within the WON cavity and the other flange is located within the enteric lumen.
FIELD: medicine. SUBSTANCE: method involves forming canals in exterior condyle of the femur and medial condyle of the tibia and taking graft and median portion of the patellar ligament with bone fragments. The patellar bone fragment has cylindric form. The tibial bone fragment has trapezoid form. The autograft is set in the bone canals and knee joint. The trapezoid bone fragment is rigidly fixed in the femur canal. The autograft is placed in the knee joint anteriorly with respect to the prepared constraint flap of the synovial tissue. When being in relaxation state, the autograft is enveloped with the flap of synovial tissue, twisted along the longitudinal axis of symmetry and its second end is attached to the tibia. All actions inside the knee joint are performed under arthroscopic control. EFFECT: enhanced effectiveness of treatment. 12 cl
Escherichia coli and Klebsiella spp. are common causes of bacteraemia, and may acquire genes encoding extended-spectrum beta-lactamases (ESBLs) or AmpC beta-lactamases (1). ESBL or AmpC producers are typically resistant to third generation cephalosporins such as ceftriaxone, but susceptible to carbapenems (1). Observational studies have been performed evaluating antibiotic choices for ESBL producers (2-9). In no study has the outcome of treatment for serious infections for ESBL producers been significantly surpassed by carbapenems (2-9).

Despite the potential advantages of carbapenems for treatment of ceftriaxone non-susceptible organisms, widespread use of carbapenems may cause selection pressure leading to carbapenem-resistant organisms. This is a significant issue since carbapenem-resistant organisms are treated with "last-line" antibiotics such as colistin. Some new beta-lactam antibiotics and beta-lactamase inhibitors, which are active against ESBL, AmpC and some carbapenemase producing organisms, are in advanced clinical development (10). However, these antibiotics are likely to be expensive and may best be held in reserve for infections where there are no alternatives. Therefore, we see a need for establishing the efficacy of a generically available alternative to carbapenems for serious infections.

The susceptibility of ESBL producers and AmpC producers to piperacillin/tazobactam is less predictable than that of carbapenems. By definition, ESBLs are inhibited by beta-lactamase inhibitors such as tazobactam (1). However, E. coli or Klebsiella may produce multiple beta-lactamase types some of which are resistant to inhibition by tazobactam. Additionally, in some cases outer membrane protein loss may contribute to resistance to tazobactam. By definition, AmpC is not inhibited by beta-lactamase inhibitors such as tazobactam. However, despite these limitations, approximately 50% or more of ceftriaxone non-susceptible E. coli or Klebsiellae remain susceptible in vitro to piperacillin/tazobactam (1).

No randomised controlled trials have yet been performed comparing different treatment options for ceftriaxone resistant Enterobacteriaceae. The largest observational study with an analysis by treatment outcome was published in February 2012 by Rodriguez-Bano and colleagues (9). They performed a post-hoc analysis of six published cohorts of patients with bacteraemia due to ESBL producing E. coli. Two nonmutually exclusive cohorts (empirical therapy and definitive therapy) were constructed and analysed separately. In both cohorts, carbapenems were not superior to beta-lactam/beta-lactamase inhibitor combinations (BLBLIC). Specifically, in the definitive therapy cohort, mortality rates at 30 days were not significantly different - 9.3% for those who received a BLBLIC and 16.7% for those who received a carbapenem (p\>0.20) (9).
A vitamin-B12-tannin complex is made by mixing aqueous solutions of a vitamin B12-active substance, e.g. cyano- or hydroxy-cobalumin and tannin and collecting the precipitate formed. A metal salt, e.g. of zinc, bismuth or cobalt 60 may also be present in which case the complex will contain the metal also.  Preferably, the tannin used is obtained by dissolving commercial tannin in water, adjusting the pH to 6.2, extracting with ethyl acetate and drying and evaporating the extract to give a crystalline product.ALSO:Pharmaceutical compositions for parenteral administration and having a protracted Vitamin B12 effect, comprise a complex compound of a Vitamin B12-active substance (e.g. cyanocobalamin or hydroxycobalamin) and tannin, suspended in a parenterally acceptable solution of aluminium monostearate in a solvent selected from vegetable oils and liquid fatty acid esters e.g. isopropyl myristate.  The complex compound may also comprise metal ions those of zinc, bismuth and cobalt 60 being mentioned. The compositions may be prepared by dissolving the aluminium monostearate in an organic solvent to form a gel into which the Vitamin B12 complex compound is stirred.  The solvent is then removed by evaporation and the residue is mixed with the oil. Alternatively, the complex, which may be prepared by precipitation from aqueous solutions of the components, may be ground into the suspension medium.  An antioxidant may be added to counteract oxidative decomposition of the tannic acid.
Following baseline evaluation, participants in this group will receive 8 weeks of digital Cognitive Behavioral Therapy for Insomnia delivered using Sleep Healthy Using the Internet (SHUTi). After the interim assessment, participants will then crossover to 8 weeks of active monitoring.
<P>PROBLEM TO BE SOLVED: To obtain a polypeptide that has hardly adverse effect, is produced without requiring such a high technique and a plenty of people, promotes plasmin activity, t-PA activity and urokinase activity and a use thereof.  <P>SOLUTION: The polypeptide promotes thrombolysis and has an amino acid sequence equal to or substantially equal to a specific amino acid sequence, its amide, its ester or its salt. The antibody against the polypeptide is obtained. The detection of the polypeptide, etc., comprises using the antibody. The thrombolysis promoter contains the polypeptide.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Sulforaphane will be applied topically to both sites for up to 7 consecutive nights. Biopsies will be obtained prior to, and immediately after this intervention, on standard photoprotected and photoexposed sites.
BACKGROUND: Workplaces are an important setting to deliver programs to reduce risk factors for noncommunicable diseases (NCDs). To help decision makers understand the most current and relevant evidence regarding effectiveness of workplace programs, we conducted an umbrella review to present a comprehensive synthesis of the large volume of literature.
METHODS: Systematic reviews of workplace interventions targeting primary risk factors for NCDs-unhealthy diet, insufficient physical activity, overweight/obesity, tobacco use, and/or excessive alcohol use-published since 2010 were sourced. For each risk factor, reviews were categorized by intervention type and quality. The most recent, high-quality review was included for each intervention type. Evidence for the effectiveness of each intervention type was then broadly classified based on the review summary findings.
RESULTS: Twenty-one reviews were included. Most reviews focused on diet (n = 5), physical activity (n = 7), or obesity (n = 9) interventions, with fewer targeting alcohol (n = 2) or tobacco (n = 2) use. Reviews of interventions focusing on individual behavior (such as education or counseling) were most common. Across diet, obesity, physical activity, and tobacco use, multicomponent interventions were consistently likely to be classified as "likely effective." Motivational interviewing and broad health promotion interventions were identified as "promising" for alcohol use.
CONCLUSION: This umbrella review identified that multicomponent workplace interventions were effective to reduce NCD risk factors. There is a gap around interventions targeting alcohol use as most syntheses lacked enough studies to draw conclusions about effectiveness. Exploring the impact of interventions that utilize policy and/or environmental strategies is a critical gap for future research.
The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visual-radiography. The dilation catheter was then withdrawn to leave the PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s. After that An RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
A method for preparing biodegradable, biocompatible microparticles. A first phase is prepared that includes a biodegradable, biocompatible polymeric encapsulating binder, and an active agent having limited water solubility dissolved or dispersed in a solvent. An aqueous second phase is prepared. The first and second phases are combined to form an emulsion in which the first phase is discontinuous and the second phase is continuous. The two phases are separated. The discontinuous first phase is washed with water, or an aqueous solution of water and a solvent for residual solvent in the first phase, to reduce the level of residual solvent in the microparticles to less than about 2% by weight of the microparticles. Also disclosed are a microencapsulated drug prepared by the method for preparing biodegradable, biocompatible microparticles, and a pharmaceutical composition that includes biodegradable and biocompatible microparticles in a pharmaceutically acceptable carrier.
A limbus-based conjunctival peritomy was created 4mm posterior to the limbus and Tenon's capsule was dissected. The AGV Plate was secured to the sclera 8 mm posterior to the limbus. The tube was trimmed to an appropriate length and inserted into the anterior chamber through a corneoscleral track. The tube was fixed to the episclera with a 10-0 nylon mattress suture. A donor sclera was fashioned to cover the exposed part of the tube and was secured to the sclera using 10-0 nylon sutures. The conjunctiva and Tenon were closed using 10-0 nylon suture.
BISMUTH-CONTAINING COMPOUNDS, COORDINATION POLYMERS, METHODS FOR MODULATING PHARMACOKINETIC PROPERTIES OF BIOLOGICALLY ACTIVE AGENTS, AND METHODS FOR TREATING PATIENTS Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson's disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient. 7R7040P 1 (CHMattr) P103435 Al J RONIAM 1 o19 cell m / NH2 surfaceI bicadhesive 5-ASA adjuvant cell P- \0 -NH2 surface bloadhesive 5-ASA adjuvant
PURPOSE:To obtain a dental material having a faint smell, low irritation, low water absorption ratio of polymer, a proper pasty viscous time and extremely high practical value, comprising a specific methacrylic acid ester-based compound. CONSTITUTION:This dental material having a faint smell and low irritation comprises methacrylic acid ester of formula I ((n) is >=2 integer; R is H or methyl) (e.g. compounds of formula II or formula III). The methacrylic acid ester-based compound is preferably blended with a copolymerizable polyfunctional or trimethylolpropane trimethacrylate). Since this curing material has excellent durability in terms of change in dimension, strength, change of color, etc., even under an extremely severe wetness such as interior of oral cavity, the curing material can be used for a long period of time. On the other hand, treatment can be done safely and hygienically by a dentist or a dental mechanic and the curing material has improved operation efficiency.
PRIMARY OBJECTIVES: I. Describe the feasibility of implementing the BBCEI. II. Describe the cultural and linguistic appropriateness of the BBCEI. III. Determine topics requiring further emphasis in the BBCEI. IV. Identify ways to enhance program content, format, and materials. OUTLINE: Participants undergo 2 tailored BBCEI sessions within 1 month. At the beginning of the first session the research nurse will present the participants with a list of common physical and social concerns. The participant will then be asked to identify 3 topics that she wants to discuss. The research nurse will discuss with the participant any relevant supportive care resources and make the appropriate referrals. At the second session the focus of the BBCEI will be on psychological and spiritual well-being.
The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has undeniably emerged as the largest global health threat to humanity in this century. SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality if the virus establishes itself in the population. The inventors have set up candidate vaccines against SARS-CoV-2. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope), as well as regions rich in epitopes whose sequences are homologous between SARS-CoV-2 and -CoV-1. Finally, the inventors have generated some specific CD40 antibodies comprising one or more SARS-CoV-2 polypeptide(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to SARS-CoV-2 polypeptides and uses thereof for vaccine purposes.
Tramadol

SEGLENTIS contains tramadol, a Schedule IV controlled substance. As an opioid, SEGLENTIS exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed SEGLENTIS. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing SEGLENTIS, and reassess all patients receiving SEGLENTIS for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as SEGLENTIS but use in such patients necessitates intensive counseling about the risks and proper use of SEGLENTIS along with frequent reevaluation for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing SEGLENTIS. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and on the proper disposal of unused drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
PURPOSE: A solid dispersion of cilostazol and polymethacrylate copolymers, and a pharmaceutical composition containing the same are provided to quickly release cilostazol and to reduce the dosage. CONSTITUTION: A solid dispersion with polymethacylate copolymers contains cilostazol. The copolymer is a copolymer of methacrylic acid and methyl methacrylate, a copolymer of methacrylic acid and ethyl acrylate, an ammonio methacrylate, or a copolymer of butyl methacrylate, (2-dimethyl aminoethyl)methacrylate, and methyl methacrylate. The solid dispersion additionally contains one or more polymers selected from a group consisting of hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, crospovidone, or a copolymer of vinylpyrrolidone and vinyl acetate. An oral pharmaceutical composition contains the solid dispersion and a pharmaceutically acceptable additive. [Reference numerals] (AA) Elution rate(%); (BB) Comparative embodiment 9; (CC) Comparative embodiment 10; (DD) Pletaal Tab.; (EE) Embodiment 7; (FF) Time(h)
BACKGROUND: Nosocomial infections with heavy disease burden are becoming a major threat to the health care system around the world. Through long-term, systematic, continuous data collection and analysis, Nosocomial infection surveillance (NIS) systems are constructed in each hospital; while these data are only used as real-time surveillance but fail to realize the prediction and early warning function. Study is to screen effective predictors from the routine NIS data, through integrating the multiple risk factors and Machine learning (ML) methods, and eventually realize the trend prediction and risk threshold of Incidence of Nosocomial infection (INI).
METHODS: We selected two representative hospitals in southern and northern China, and collected NIS data from 2014 to 2021. Thirty-nine factors including hospital operation volume, nosocomial infection, antibacterial drug use and outdoor temperature data, etc. Five ML methods were used to fit the INI prediction model respectively, and to evaluate and compare their performance.
RESULTS: Compared with other models, Random Forest showed the best performance (5-fold AUC = 0.983) in both hospitals, followed by Support Vector Machine. Among all the factors, 12 indicators were significantly different between high-risk and low-risk groups for INI (P < 0.05). After screening the effective predictors through importance analysis, prediction model of the time trend was successfully constructed (R2 = 0.473 and 0.780, BIC = -1.537 and -0.731).
CONCLUSIONS: The number of surgeries, antibiotics use density, critical disease rate and unreasonable prescription rate and other key indicators could be fitted to be the threshold predictions of INI and quantitative early warning.